663TiP BNT323-01: A phase III trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)
J-H. Kim, Hanna Mellin Dahlstrand, P-H. Wang, K.N. Moore et autres
kr, se, tw, us, cz, it, au, es, cn, de, tr, ca, be, fr, gb (code pays fourni par la source)